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T
here is little doubt that the consequences of the current
severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) pandemic on healthcare, infrastruc-
ture as well as on our socio-economic life will be
severe and long-lasting. The high infectivity of this “new” virus, a
high frequency of asymptomatic carriers, the lack of herd
immunity and a range of rare presentations, including fatal
cytokine storms, are posing major challenges.1
Fortunately for our young patients, severe COVID-19 disease
mainly affects adults and otherwise healthy children and young
adults appear to be relatively spared. Reports on COVID-19
disease showed that less than 1% of the cases were in children
younger than 10 years of age.2 Lu et al reported on the spectrum
of illness from SARS-CoV-2 infection in 171 children. In contrast
with infected adults, most infected children appeared to have a
milder clinical course. During the course of hospitalization, only
3 children required intensive care support and invasive
mechanical ventilation; all 3 had coexisting medical problems
(hydronephrosis, leukemia receiving maintenance chemotherapy
and intussusception). There was one death, a 10-month-old child
with intussusception who developed multi-organ failure and died
4 weeks after admission. Asymptomatic infections were reported
in 15.8% of infected children.3 A nationwide case series of 2135
pediatric patients with COVID-19 reported to the Chinese center
for disease control and prevention showed that more than 90%
of all patients had asymptomatic, mild, or moderate disease.
Younger children, particularly infants, were relatively more
vulnerable to SARS-CoV-2 infection. The proportions of severe
and critical cases were 10.6%, 7.3%, 4.2%, 4.1%, and 3.0% for
the age groups <1, 1 to 5, 6 to 10, 11 to 15, and ≥16 years,
respectively.4
AKawasaki-likemultisystem inflammatory syndrome in children
has recently been reported in a number of countries associated with
the SARS-CoV-2 pandemic.5,6 Others reported a COVID-19 post-
infectious cytokine release syndrome that had features similar to
Kawasaki Disease and Toxic Shock Syndrome.7 Interestingly and
possibly related to this inflammatory picture, variations in NK cell
and perforin function which are associated with virally induced
HLH may also influence the severity of the clinical course and
mortality ratesof SARS-CoV-2 infections.8Whittaker et aldescribed
a case series of 58 children from England with a wide spectrum of
presenting symptoms and signs and disease severity, ranging from
fever and inflammation to myocardial injury, shock, and develop-
ment of coronary artery aneurysms who met the criteria for the
newly defined pediatric inflammatory multisystem syndrome
temporally associated with severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) (PIMS-TS) which differed from other
pediatric inflammatory entities.9
In contrast to children in general, data on the clinical
manifestations of SARS-CoV-2 infections in pediatric hemato-
oncology patients are scarce and anecdotal. An 8-year-old child
undergoing myelosuppressive chemotherapy for T-cell acute
lymphoblastic leukemia in a Wuhan hospital developed respira-
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tory failure, eventually requiring mechanical ventilation.3,10 A 1-
year-old girl with acute myeloid leukemia receiving chemothera-
py at the Meyer Children’s Hospital in Florence, Italy, developed
temperatures and increased bilateral reticular marking on chest
X-ray but fortunately fully recovered without needing any airway
support.11 Hrusak et al made a flash survey on COVID-19
incidence and severity among children on anticancer treatment.12
Reports from 25 countries worldwide, covering a population of
approximately 10,000 children and young people on anti-cancer
therapy, identified only nine children that tested positive for
SARS-CoV-2. Eight of the nine cases had asymptomatic to mild
disease and one had just been diagnosed. This consortium is
currently collecting additional and more detailed long-term data
on COVID-19 incidence in children and adolescents with cancer
as well as information on the testing policies of the participating
centers. At the Memorial Sloan Kettering Cancer Center (MSK)
pediatric cancer patients were screened for 1 month (March 10 to
April 12, 2020) for SARS-CoV-2. Of the 20 patients that tested
positive only one required noncritical care hospitalization for
COVID-19-related symptoms. Three other patients without
significant COVID-19 symptoms were admitted for concomitant
fever and neutropenia, cancer morbidity, or planned chemother-
apy. All other pediatric patients were managed at home.13 In
Italy, data were collected in the 6 pediatric hemato-oncology
centers in Lombardia over the first 8 weeks of the pandemic
(February 20 to April 15, 2020). Twenty-one cases of COVID-19
infection were identified. Fifteen of these patients were on
treatment, and six were in follow up after elective discontinuation
of treatment. Only two patients experienced complications: one,
with a diffuse intrinsic pontine glioma and respiratory im-
pairment, developed pneumonia requiring respiratory support;
another, with refractory Hodgkin lymphoma and prior medias-
tinal irradiation developed atypical bilateral pneumonia with
mild symptoms.14 Cases of Kawasaki-like disease or HLH have
so far not been reported in pediatric oncology patients.
The situation is similar for children with benign hematological
disorders. The UK national hemoglobinopathy panel reported
195 cases of COVID-19 of which only 20 were children. 10.5%
of adults required intensive care for airways support compared to
none of the children.15 In France, the PICU at theHôpital Necker-
Enfants malade reported four children with sickle cell disease and
COVID-19; all required noninvasive airways support and all
made full recovery.16 Data on patients with primary immuno-
deficiencies are also scarce, even more so in the pediatric
population. Whilst initially there were significant concerns that
this population may be extremely vulnerable to SARS-CoV-2,
many may, conversely, be at lower risk. There are some data
suggesting that patients with lymphopenia, for instance in
untreated patients with HIV, may have a less severe clinical
course because they lack T lymphocytes, which may reduce the
risk of acute respiratory distress syndrome and other hyper-
inflammatory states.17 One systematic review of children and
adults receiving immunosuppression reported sixteen relevant
articles, which identified 110 immunosuppressed patients
including children, with cancer, following transplantation and
with immunodeficiency. It concluded that immunosuppression
may be associated with a more favorable outcome as compared
with other comorbidities.18 This is supported by a recent study in
adults that did not identify chemotherapy as a risk factor for
mortality from COVID-19 disease.19 In contrast, Liu and
colleagues followed the systemic review with a meta-analysis
and concluded that immunosuppression and immunodeficiency
were associated with increased risk of severe COVID-19 disease
with the vast majority of patients being adults often with
additional co-morbidities.10 This underlines the difficulty on
obtaining good quality information on COVID-19 in pediatric
patients at the present time. Based on the current available
information, there may be more concern for patients whose
immunodeficiency predisposes to hyper-inflammation, such as
hemophagocytic lymphohistiocytosis or chronic granulomatous
disease. Until more definite information becomes available, a
counsel of prudence and shielding this vulnerable population
would seem reasonable, as adopted by many national and
specialist society guidelines.
Together, these reports suggest that children with hematologi-
cal disease, including children receiving anti-cancer chemothera-
py and children with inborn errors of the immune-system, may
have a mild or asymptomatic course of COVID-19; however,
children with comorbidities, including immune suppression and
malignancy, can have severe disease20 and too few hematology
patients have so far been affected to assess the definitive risk of
SARS-CoV-2 infection on this patient population.
We still have a lot to learn a lot about COVID-19 in our patient
population and many open questions remain, including:
 What are the biomarkers predicting the course and outcome of
COVID-19 in children and young people with hematological
disorders?
 How will our patients respond to a SARS-CoV-2 vaccine once
such a procedure becomes available? What should a proper
vaccination program look like when the child is receiving
immunosuppressive treatment or following a stem-cell trans-
plantation?
 Are there genetic variants that underlie susceptibility to
COVID-19 and, if so, are they linked to tumor predisposition
and treatment response?So far, theCOVIDHumanGeneticEffort
(https://www.covidhge.com/), an international consortium that
aims to discovermonogenic inborn errors of immunity underlying
severe forms of COVID-19 in previously healthy individuals does
not consider children with malignancies.
How has the SARS-CoV-2 pandemic affected
the treatment of pediatric hematology patients?
An important and widely discussed potential risk for cancer
patients is delayed diagnosis and treatment during this SARS-
CoV-2 pandemic. Delayed diagnosis could be due to a decreased
access of young patients to their health care provider and/or
avoidance of families to seek medical advice because of the fear of
infection. Delays in therapy may occur due to delay or
cancellation of “non-essential” treatments, including cancer
surgery, or imaging and stroke risk screening in sickle cell disease.
Hematopoietic stem cell transplant activity has been curtailed,
with many services treating only urgent cases. Furthermore,
accessing unrelated donors has become more difficult, as they
may be unavailable to donate because of illness or isolation –
testing for SARS-CoV-2 and awaiting negative results has further
slowed down the normal process. Current recommendations are
to receive stem cells and freeze them before commencing
conditioning, which may impair engraftment and immune
reconstitution, especially in case of unfavorable donor-recipient
weight disparity, when the number of cells in the graft is expected
to be suboptimal.
As far as we know, experience has been different in different
countries throughout Europe. While in Lombardia, Italy, a dip
had been observed in newly diagnosed pediatric cancer
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patients,14 no such reduction has been seen in referrals in other
countries such as the Austria, Israel or the Netherlands. Even in
Lombardia, this dip was in part due to fewer out-of-region and
international referrals.
In addition, it has been speculated whether social distancing
and home isolation might actually lower the incidence of B-
lineage ALL, as was observed after the SARS epidemic in 2003.21
Alternatively, spreading of SARS-CoV-2 in naive populations, as
has been described for other viruses such as the AH1N1 swine flu
virus,22 could be linked to small outbreak clusters of B-precursor
ALL in kindergartens and schools. Future studies will need to
provide further insight into the epidemiological consequences of
this pandemic on the incidence of ALL.
Although most pediatric hematologists have anecdotal experi-
ence of individual patients that presented late, on a whole there
does not seem to be significant barrier of children accessing health
services for diagnosis and treatment in Europe. The important
message that families with ill children need to seek medical advice
and that general practitioners should continue to refer patients
with a differential diagnosis of cancer, has come across.
Treatment of pediatric hematology patients has continued, albeit
under significantly more difficult circumstances.
The time and resources used todevelopguidelines on isolation of
children under treatment (with and without symptoms/SARS-
CoV-2 positivity), screening guidelines (for patients with and
without symptoms, before anesthesia), reorganizing outpatients
clinics (eg, implementation of social distancing, video consulta-
tions), setting up clinical pathways to prevent SARS-CoV
positivity23 or treat COVID-19 patients have been tremendous.
This has been further complicated by the plenitude of advice and
recommendations, sometimes conflicting, even at local level.
Whom, when and how often to screen?Which personal protective
equipment touse bypatients andhealth care professionals inwhich
situation and when? What is an aerosol-generating procedure?
Whatever we have done has been associated with a low
incidence of SARS-CoV-2 infections in our patients. All efforts
and measures will need to be carefully assessed and looked at in
the context of potential future pandemics.What have we learned?
And what can we do better or more efficiently next time round?
Wewill also need to carefully look now how this whole pandemic
has affected our young patients, their parents and siblings to
provide adequate multidisciplinary team support: social isola-
tion, including lack of visits from close relatives and friends
during long hospital stays, anxieties caused by the pandemic or
discomfort from repeated COVID testing in young children, their
guardians and staff.
What is clear is that pediatric hematology research has come to
a standstill. Researchers have been unable to go to their labs.
Clinical trials have been put on hold as safety of trial participants
has been the first priority. Charities are seeing or expecting a
significant drop in fundraising. The largest charity in Europe
funding cancer research, Cancer Research UK, expects a drop of
20% to 25% in their fundraising income (https://www.cancer
researchuk.org/about-us/cancer-news/press-release/2020-03-30-
cancer-research-uk-estimates-25-per-cent-drop-in-fundraising-in
come-due-to-coronavirus) and expects to make difficult cuts in
research funding. Governmental agencies will also struggle to
fund research in the context of a shrinking economy, the necessity
to fund packages to stimulate the economy and a decreased tax
income and, understandably, research funds will be shifted
toward research on SARS-CoV-2 infections. Our voice and, even
more importantly, the voice of the different parent organizations
active in the pediatric hematology space will be crucial to lobby
governments to keep research for our young patients on the
agenda; and as a community, even more than ever, we need to
support our different charities in raising awareness and money.
Conclusion/Summary
As health care professionals, we need to provide patients and
families but also health care providers in primary secondary care
with clear information. Access to medical care for diagnosis and
treatment of childhood cancer and other hematological disorders
is paramount and the risk of hematological disease clearly
outweighs the risks of SARS-CoV-2 infection in our patient
population. International consensus guidance on prioritizing
diagnosis and treatment for pediatric cancers during the COVID-
19 pandemic have recently been published.24
Fortunately, the spread of SARS-CoV-2 in our patient
population has been limited, the course of disease has been mild
in many children affected, even if severely immunocompromised,
and, with an incredible effort from our multidisciplinary teams,
we have been able to provide good care for our patients
throughout this first phase of the pandemic. The medium- and
long-term effects of the COVID-19 pandemic on society,
including funding of health care and research, and the direct
and indirect effects of the COVID-19 pandemic on our patients,
however, remain to be carefully monitored. In times of
challenging socio-economic decisions that are likely to affect
both health care and research, it will be important to ensure that
adequate resources and funding will be available for the
treatment of our patients and for innovation and research.
Working closely together with all the different stakeholders active
in the pediatric hematology space (including parent/survivor
groups, charities, research funders, governmental organizations,
insurance providers and pharma) will be crucial to keep the needs
of our patients on the agenda.
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